Magnet Biomedicine wants to give difficult proteins a useful introduction

A difficult protein is rather like a guest who refuses to shake hands. You can keep offering the same hand, or introduce someone it already knows. Magnet Biomedicine is working on the second possibility. Its small molecules bring a disease-related protein together with a selected companion, called a presenter. The useful event happens in the relationship between them.

That sounds like a modest alteration to the usual drug-discovery question. Instead of asking what binds to this protein, ask what helps another protein engage it. Yet the alteration opens a different route through a familiar obstacle: disease targets that conventional small molecules struggle to reach. The chemistry is small. The change in the question is considerable.

The old drugs knew something first

Magnet’s intellectual starting point predates the company. Cyclosporin and rapamycin showed that a medicine could work through induced protein proximity. Researchers did not initially understand all the machinery behind those effects. In the early 1990s, Harvard chemical biologist Stuart Schreiber helped explain how cyclosporin brings proteins into a therapeutic interaction. A successful medicine had supplied a clue before science supplied the explanation.

Schreiber is now one of Magnet’s five scientific co-founders, alongside Benjamin Cravatt, David Spiegel, Richa Saxena and Michael Rosbash, who shared the 2017 Nobel Prize in Physiology or Medicine. Their expertise spans chemical biology, chemoproteomics and human genetics. It is a useful combination for a problem that requires both choosing the right disease biology and finding chemistry that can act on it.

The business emerged from stealth in September 2023 with a $50 million Series A co-led by Newpath Partners and ARCH Venture Partners. Its premise was that better proteomics, screening and biological analysis could make useful molecular glues less dependent on chance discovery. An old mechanism might support a more deliberate search.

Three participants, one useful inhibition

TrueGlue combines proprietary chemical libraries, screening technologies and the strategic selection of target and presenter proteins. The goal is a cooperative three-part complex: the small molecule, the presenter and the disease target. With a molecular glue inhibitor, the resulting association inhibits the target. Binding alone is insufficient; the introduced relationship has to produce the intended biological effect.

The presenter makes this particularly interesting. If a drug’s action depends on a protein concentrated in certain tissues, that dependency could help restrict where the drug acts. Magnet describes tissue specificity as a potential benefit. It is a design ambition, rather than permission to assume that a future pill will spare every healthy cell.

There is another distinction. Much molecular glue research recruits cellular machinery that marks proteins for destruction. Magnet wants a broader repertoire. As CEO Brian Safina put it at launch: “There are other biological mechanisms that one can take advantage of.” Its current presentation concentrates on molecular glue inhibitors intended as oral medicines.

“There are other biological mechanisms that one can take advantage of.”Brian Safina / September 2023

A pill-shaped ambition, with named targets

The current pipeline gives that idea something concrete to hold. Magnet lists an ST2 program for COPD and asthma, and a TL1A program for multiple indications, both at lead optimization. Additional immunology and oncology work sits in early discovery. These stages concern finding and improving prospective medicines; they do not establish that a treatment works in patients.

For immunology, Magnet describes a proprietary “Super Presenter” that helps its inhibitors engage difficult extracellular targets. The name has the confidence of a comic-book character. The task is sober: pursue disease biology that has been difficult to address with oral small molecules. An effective pill could offer a convenient alternative where treatment otherwise involves a biologic, but convenience must arrive with acceptable safety and efficacy.

The billion-dollar number has conditions

In February 2025, Lilly signed an agreement to discover, develop and commercialize molecular glue therapeutics in oncology using TrueGlue. For Magnet, this is the clearest disclosed example of the commercial model: develop a discovery capability and pipeline, then combine them with a pharmaceutical partner’s development expertise through collaboration and licensing.

The arithmetic deserves attention. Magnet is eligible for up to $40 million in upfront and near-term payments and an equity investment. Additional development, regulatory and commercial milestones could total more than $1.25 billion, with tiered royalties on global net sales. Those milestones depend on future achievements. A large possible total describes the contract’s reach, not money already earned.

Lilly is a partner and licensee; patients are the intended eventual beneficiaries. TrueGlue is a research platform used to generate medicines, rather than a subscription tool a physician can open. The financing and deal support the work, but neither substitutes for evidence that a particular candidate helps people.

The competition is over what proximity can do

Magnet belongs to the induced-proximity corner of biotechnology. Neomorph pursues molecular glue degraders; Ambagon builds around the 14-3-3 protein family. Magnet’s emphasis is rational presenter selection and inhibition beyond degradation. These are related answers to difficult drug-discovery problems, with different biological machinery. A suitable approach depends on the target and the desired effect.

The useful lesson for a reader outside biotechnology is to reconsider the unit being designed. Magnet treats a protein pair as part of the solution. That idea is portable: examine whether a complementary relationship changes a problem that resists isolated optimization. The chemistry, however, is unforgiving. The presenter must be suitable, the complex productive and the eventual medicine tolerable.

Magnet appointed business-development executive Bharat Reddy in November 2025 and chief medical officer Nick Vlahakis in January 2026. The latter appointment accompanied an explicit push toward human proof of concept. That is where the introduction gets its examination: not whether two proteins can meet, but whether their meeting improves a patient’s life.